Small cell transformation in EGFR-mutated non-small cell lung cancer (EGFR plus NSCLC): Efficacy of immune checkpoint inhibitors or tyrosine kinase inhibitors combined with platinum-based chemotherapy

被引：0

作者：

Saalfeld, F. C. ^{[1
]}

Moeller, J. ^{[1
]}

Michels, S. ^{[2
]}

Grohe, C. ^{[3
]}

Wiesweg, M. ^{[4
]}

Schubart, C. ^{[5
]}

Alt, J. ^{[6
]}

Griesinger, F. ^{[7
]}

Kauffmann-Guerrero, D. ^{[8
]}

Kulhavy, J. ^{[9
]}

Overbeck, T. R. ^{[10
]}

Pelusi, N. ^{[11
]}

Rohde, G. ^{[12
]}

Wesseler, C. ^{[13
]}

Vathiotis, I. ^{[14
]}

Veluswamy, R. ^{[15
]}

Illini, O. M. ^{[16
]}

Rothschild, S. I. ^{[17
]}

Christopoulos, P. ^{[18
]}

Wermke, M. ^{[1
]}

机构：

[1] Tech Univ Dresden, Univ Hosp Carl Gustav Carus Dresden, Clin Internal Med 1, Dresden, Germany

[2] Univ Cologne, Univ Hosp, Dept Internal Med 1, Cologne, Germany

[3] ELK Berlin, Dept Resp Dis, Berlin, Germany

[4] Univ Duisburg Essen, Dept Med Oncol, West German Canc Ctr, Essen, Germany

[5] Friedrich Alexander Univ Erlangen Nurnberg FAU, Univ Hosp Erlangen, Inst Pathol, Erlangen, Germany

[6] Johannes Gutenberg Univ Mainz, Dept Hematol & Oncol, Univ Med Ctr, Mainz, Germany

[7] Univ Med Oldenburg, Pius Univ Hosp, Dept Hematol & Oncol, Oldenburg, Germany

[8] Univ Munich LMU, Univ Hosp, Div Resp Med & Thorac Oncol, Dept Med, Munich, Germany

[9] Univ Hosp Wuerzburg, Comprehens Canc Ctr Mainfranken, Early Clin Trial Unit ECTU, Wurzburg, Germany

[10] Univ Gottingen, Univ Med Ctr Gottingen, Dept Hematol & Med Oncol, Gottingen, Germany

[11] Univ Hosp Bonn UKB, Inst Pathol, Bonn, Germany

[12] Johannes Wolfgang Goethe Univ, Med Clin 1, Dept Resp Med, Univ Klinikum Frankfurt, Frankfurt, Germany

[13] Klinikum Harburg, Asklepios Tumorzentrum Hamburg, Dept Pneumol, Hamburg, Germany

[14] Sotiria Thorac Dis Hosp Athens, Dept Med 3, Athens, Greece

[15] Icahn Sch Med Mt Sinai, Tisch Canc Inst, Div Hematol & Med Oncol, New York, NY USA

[16] Klin Floridsdorf, Vienna Healthcare Grp, Karl Landsteiner Inst Lung Res & Pulm Oncol, Dept Resp & Crit Care Med, Vienna, Austria

[17] Cantonal Hosp Baden, Ctr Oncol Hematol, Baden, Switzerland

[18] Univ Heidelberg Hosp, Thoraxklin, Heidelberg, Germany

来源：

ANNALS OF ONCOLOGY | 2023年 / 34卷

关键词：

D O I：

10.1016/j.annonc.2023.09.2369

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

1336P

引用

页数：1

共 50 条

[41] Predictors of Outcomes in Patients with EGFR-Mutated Non-Small Cell Lung Cancer Receiving EGFR Tyrosine Kinase Inhibitors: A Systematic Review and Meta-Analysis
Buonerba, Carlo
Iaccarino, Simona
Dolce, Pasquale
Pagliuca, Martina
Izzo, Michela
Scafuri, Luca
Costabile, Ferdinando
Riccio, Vittorio
Ribera, Dario
Mucci, Brigitta
Carrano, Simone
Picozzi, Fernanda
Bosso, Davide
Formisano, Luigi
Bianco, Roberto
De Placido, Sabino
Di Lorenzo, Giuseppe
CANCERS, 2019, 11 (09)
[42] Targeting non-small cell lung cancer with small-molecule EGFR tyrosine kinase inhibitors
Singh, Mahaveer
Jadhav, Hemant R.
DRUG DISCOVERY TODAY, 2018, 23 (03) : 745 - 753
[43] First- versus Third-Generation EGFR Tyrosine Kinase Inhibitors in EGFR-Mutated Non-Small Cell Lung Cancer Patients with Brain Metastases
Tatineni, Vineeth
O'Shea, Patrick J.
Ozair, Ahmad
Khosla, Atulya A.
Saxena, Shreya
Rauf, Yasmeen
Jia, Xuefei
Murphy, Erin S.
Chao, Samuel T.
Suh, John H.
Peereboom, David M.
Ahluwalia, Manmeet S.
CANCERS, 2023, 15 (08)
[44] The immune profile of EGFR-mutated non-small-cell lung cancer at disease onset and progression after tyrosine kinase inhibitors therapy
Fumagalli, Caterina
Guerini-Rocco, Elena
Vacirca, Davide
Passaro, Antonio
de Marinis, Filippo
Barberis, Massimo
IMMUNOTHERAPY, 2018, 10 (12) : 1041 - 1045
[45] COMMON AND UNCOMMON EGFR MUTATIONS AND THEIR IMPACT ON RESPONSE TO EGFR TYROSINE-KINASE INHIBITORS AND PLATINUM-BASED CHEMOTHERAPY IN NON-SMALL CELL LUNG CANCER (NSCLC): LATIN-AMERICAN CONSORTIUM FOR THE INVESTIGATION OF LUNG CANCER (CLICAP)
Arrieta, Oscar
Cardona, Andres
Campos Parra, Alma D.
Corrales-Rodriguez, Luis
Sanchez-Reyes, Roberto
Katherine Rodriguez, July
Carranza, Hernan
Vargas, Carlos
Zuniga-Orlich, Carlos
Juarez-Villegas, Melissa
Rosell, Rafael
JOURNAL OF THORACIC ONCOLOGY, 2013, 8 : S482 - S482
[46] Capmatinib plus nazartinib in patients with EGFR-mutated non-small cell lung cancer
Felip, Enriqueta
Metro, Giulio
Soo, Ross A.
Wolf, Juergen
Solomon, Benjamin J.
Tan, Daniel S. W.
Ardizzoni, Andrea
Lee, Dae Ho
Sequist, Lecia V.
Barlesi, Fabrice
Ponce-Aix, Santiago
Abreu, Delvys Rodriguez
Campelo, Maria Rosario Garcia
Sprauten, Mette
Djentuh, Leslie O'Sullivan
Smith, Nathalie
Jary, Aline
Belli, Riccardo
Glaser, Sabine
Zou, Mike
Cui, Xiaoming
Giovannini, Monica
Yang, James Chih-Hsin
EUROPEAN JOURNAL OF CANCER, 2024, 208
[47] Retrospective Analysis of Immune Checkpoint Inhibitors in Patients with EGFR Mutated Non-Small Cell Lung Cancer in a Japanese Cohort
Yamada, T.
Shiotsu, S.
Tanimura, K.
Harada, T.
Kubota, Y.
Takeda, T. T.
Watanabe, S.
Uchino, J.
Takayama, K.
JOURNAL OF THORACIC ONCOLOGY, 2018, 13 (10) : S503 - S503
[48] Combined action of EGFR tyrosine kinase inhibitors and whole-brain radiotherapy on EGFR-mutated non-small-cell lung cancer patients with brain metastasis
Lu, Yunyun
Fan, Yun
ONCOTARGETS AND THERAPY, 2016, 9 : 1135 - 1143
[49] Adjuvant EGFR tyrosine kinase inhibitors for patients with resected EGFR-mutated non-small-cell lung cancer: a network meta-analysis
Tian, Wentao
Tan, Nuopei
Ke, Jiawen
Zou, Ji'an
Liu, Xiaohan
Pan, Yue
Zeng, Yue
Peng, Yurong
Wu, Fang
FUTURE ONCOLOGY, 2022, 18 (21) : 2695 - 2708
[50] Management of leptomeningeal metastases in EGFR mutated non-small cell lung cancer: Analysis of tyrosine kinase inhibitors sequence
Flippot, R.
Auclin, E.
Biondani, P.
Le Rhun, E.
Adam, J.
Planchard, D.
Caramella, C.
Le Pechoux, C.
Lacroix, L.
Gazzah, A.
Mezquita, L.
Besse, B.
ANNALS OF ONCOLOGY, 2018, 29 : 523 - 523

← 1 2 3 4 5 →